ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology2019
Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies.
Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Tunable regional targeting of self-assembling peptide nanomaterials in acute myocardial infarction.Advanced nanobiomed research · 2026Article
- Article
- Review
- Doxorubicin-Incorporated Nanoparticles Composed of Ce6-Conjugated Hyaluronic Acid-International journal of molecular sciences · 2026Article
- Lutein Modulates Stress-Responsive Signaling Pathways in THLE-2 Human Hepatocytes Under Intestinal Failure-Associated Liver Disease Conditions.Molecules (Basel, Switzerland) · 2026Article
- Design, synthesis, and biological evaluation of sulfonamide-functionalized pyridine carbothioamides as potent tubulin-targeting anticancer agents.RSC medicinal chemistry · 2026Article
- Enhancing the Safety of Nanoparticles in Medicine: Highlights of Progress and Critical Objectives.International journal of nanomedicine · 2026Review
- Bioinspired micro-structured fibers for biomedical applications.Bioactive materials · 2025Review
- Cholesterol Functionalized Nanoparticles Are Effective against Helicobacter pylori, the Gastric Bug: A Proof-of-Concept Study.Advanced healthcare materials · 2025Article
- Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy.Pharmaceutics · 2024Article
- Safety Landscape of Therapeutic Nanozymes and Future Research Directions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- A translational framework to DELIVER nanomedicines to the clinic.Nature nanotechnology · 2024Review
- Light-Activated Anti-Vascular Combination Therapy against Choroidal Neovascularization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Design of a nanozyme-based magnetic nanoplatform to enhance photodynamic therapy and immunotherapy.Journal of pharmaceutical analysis · 2024Article
- Synthesis and toxicity of monothiooxalamides against human red blood cells, brine shrimp (Heliyon · 2024Article
- Poly(ethylene Glycol) (PEG)-OligoRNA Hybridization to mRNA Enables Fine-Tuned Polyplex PEGylation for Spleen-Targeted mRNA Delivery.Small science · 2024Article
- Cellular uptake, intracellular behavior, and acute/sub-acute cytotoxicity of a PEG-modified quantum dot with promisingHeliyon · 2023Article
- Sertaconazole-repurposed nanoplatform enhances lung cancer therapy via CD44-targeted drug delivery.Journal of experimental & clinical cancer research : CR · 2023Article
- Size Matters? A Comprehensive In Vitro Study of the Impact of Particle Size on the Toxicity of ZnO.Nanomaterials (Basel, Switzerland) · 2023Article
- Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
As nanomedicines have the potential to address many currently unmet medical needs, the early identification of regulatory requirements that could hamper a smooth translation of nanomedicines from the laboratory environment to clinical applications is of utmost importance. The blood system is especially relevant as many nanomedicinal products that are currently under development are designed for intravenous administration and cells of the blood system will be among the first biological systems exposed to the injected nanomedicine. This review collects and summarizes the current knowledge related to the blood compatibility of nanomedicines and nanomaterials with a potential use in biomedical applications. Different types of nanomedicines were analyzed for their toxicity to the blood system, and the role of their physicochemical properties was further elucidated. Trends were identified related to: (a) the nature of the most frequently occurring blood incompatibilities such as thrombogenicity and complement activation, (b) the contribution of physicochemical properties to these blood incompatibilities, and (c) the similarities between data retrieved from in vivo and in vitro studies. Finally, we provide an overview of available standards that allow evaluating the compatibility of a material with the blood system. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials Therapeutic Approaches and Drug Discovery > Emerging Technologies Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.